ALDH5A1 Knockout Jurkat Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population with targeted disruption of the ALDH5A1 gene in Jurkat T lymphocytes. This product is supplied as a heterogeneous pool of edited cells, avoiding clonal selection bottlenecks and enabling functional analyses of succinic semialdehyde dehydrogenase (SSADH) deficiency at the population level.
Jurkat cells are an immortalized human T lymphocyte line isolated from a patient with acute T cell leukemia. They serve as a widely adopted model for T cell receptor signaling, activation-induced apoptosis, and HIV infection. Their robust proliferation and well-defined signaling networks make them a reliable host for investigating metabolic pathway perturbations, particularly those intersecting with immune function.
ALDH5A1 encodes mitochondrial SSADH, which catalyzes the NAD+-dependent oxidation of succinic semialdehyde to succinate in the GABA degradation shunt. The enzyme functions downstream of GABA transaminase (ABAT) and is positively regulated by transcription factors SP1 and NF-Y, as well as by T cell receptor stimulation and interleukin-2 (IL-2) signaling. Disruption of ALDH5A1 blocks this conversion, leading to accumulation of succinic semialdehyde and its reduced derivative gamma-hydroxybutyrate (GHB), while diminishing succinate supply to the TCA cycle. The resulting metabolic dysregulation alters mitochondrial respiration, disrupts NAD+/NADH balance, and can provoke excessive generation of reactive oxygen species.
In the Jurkat T cell context, this knockout model dissects the immunometabolic repercussions of GABA shunt impairment. Succinate acts as an inflammatory signal and TCA cycle intermediate, and its depletion may hinder activation-driven metabolic reprogramming. The polyclonal population captures a spectrum of metabolic adaptations, facilitating studies of GHB-mediated neurotoxicity and succinate-dependent epigenetic modulation. This system thus bridges inherited SSADHD pathology and T cell biology, enabling exploration of how GABAergic metabolites influence immune cell function and mitochondrial fitness.
Representative applications include modeling succinic semialdehyde dehydrogenase deficiency through LC-MS-based GHB quantification and SSADH enzyme activity assays, evaluating mitochondrial respiration by Seahorse analysis and flow cytometric detection of mitochondrial ROS, and measuring apoptosis via annexin V staining. Western blotting confirms ALDH5A1 protein loss, while metabolomic profiling delineates changes in GABA shunt intermediates. The cells are suitable for pharmacological rescue studies and co-culture experiments. For additional technical details, please contact Ascent Research.
